5.075

6.31% -0.315

Protara Therapeutics Inc (TARA)

Overview News Price History Option Chain Financials Discussions Forecast

Protara Therapeutics Inc stock is traded at $5.075, with a volume of 1.20M. It is down -6.31% in the last 24 hours and down -9.50% over the past month. Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Previous Close:

$5.39

Open:

$5.39

24h Volume:

1.20M

Relative Volume:

1.59

Market Cap:

$271.69M

Revenue:

Net Income/Loss:

$-42.05M

P/E Ratio:

-1.7996

EPS:

-2.82

Net Cash Flow:

$-35.26M

1W Performance:

-3.81%

1M Performance:

-9.50%

6M Performance:

+74.74%

1Y Performance:

-13.68%

1-Day Range:

$5.03

$5.465

1-Week Range:

$5.03

$5.80

52-Week Range:

$2.77

$7.82

Protara Therapeutics Inc Stock (TARA) Company Profile

Name

Protara Therapeutics Inc

Sector

Healthcare (1126)

Industry

Biotechnology (624)

Phone

646-844-0337

Address

345 PARK AVENUE SOUTH, NEW YORK, NY

Employee

Twitter

Next Earnings Date

2025-03-05

Latest SEC Filings

TARA's Discussions on Twitter

Compare TARA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TARA Protara Therapeutics Inc	5.07	288.84M	0	-42.05M	-35.26M	-2.82
VRTX Vertex Pharmaceuticals Inc	467.85	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	773.46	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	405.59	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	801.70	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	174.74	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-16-25	Initiated	Scotiabank	Sector Outperform
Mar-14-25	Initiated	Cantor Fitzgerald	Overweight
Jul-10-23	Resumed	Guggenheim	Buy
Jun-04-21	Initiated	H.C. Wainwright	Buy
Feb-17-21	Initiated	Oppenheimer	Outperform
Oct-19-20	Initiated	Cowen	Outperform
Jul-29-20	Initiated	Guggenheim	Buy

View All

Protara Therapeutics Inc Stock (TARA) Latest News

06:36 AM

FDA grants breakthrough therapy designation to Protara’s LM treatment By Investing.com - Investing.com Nigeria

06:36 AM

04:24 AM

Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share - MSN

04:24 AM

Jan 05, 2026

Protara Therapeutics updates on TARA-002 development - The Pharma Letter

Jan 05, 2026

Protara, CeriBell rise on FDA breakthrough designations (TARA:NASDAQ) - Seeking Alpha

Jan 05, 2026

Protara Therapeutics (TARA) Gains FDA Designations for TARA-002 - GuruFocus

Jan 05, 2026

FDA grants breakthrough therapy designation to Protara’s LM treatment - Investing.com

Jan 05, 2026

Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations - The Manila Times

Jan 05, 2026

FDA fast-tracks new cell therapy for kids with rare lymphatic disorder - Stock Titan

Jan 05, 2026

Jan 03, 2026

Protara Therapeutics’ TARA-002 Study: A Potential Game-Changer for Lymphatic Malformations - MSN

Jan 03, 2026

Jan 02, 2026

Levels Update: How forex fluctuations impact Protara Therapeutics Inc 1KPA stock2025 Historical Comparison & Fast Entry and Exit Trade Plans - moha.gov.vn

Jan 02, 2026

Dec 25, 2025

Assenagon Asset Management S.A. Invests $1.34 Million in Protara Therapeutics, Inc. $TARA - Defense World

Dec 25, 2025

Dec 24, 2025

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 - Sahm

Dec 24, 2025

Dec 23, 2025

Sentiment Watch: Can Protara Therapeutics Inc stock attract ESG capital inflows2025 EndofYear Setup & Weekly High Potential Stock Alerts - moha.gov.vn

Dec 23, 2025

Dec 22, 2025

Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Dec 22, 2025

Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Dec 22, 2025

Dec 21, 2025

Why analysts recommend Protara Therapeutics Inc. (1KPA) stockJuly 2025 Setups & Free Low Drawdown Momentum Trade Ideas - Улправда

Dec 21, 2025

Dec 20, 2025

Resistance Check: Is Protara Therapeutics Inc. (1KPA) stock attractive for dividend growth2025 Technical Patterns & Fast Entry Momentum Trade Alerts - moha.gov.vn

Dec 20, 2025

Dec 19, 2025

Why Protara Therapeutics Inc. stock could outperform in 2025Quarterly Risk Review & Stepwise Trade Execution Plans - Улправда

Dec 19, 2025

Can Protara Therapeutics Inc. stock attract ESG capital inflowsPrice Action & Daily Chart Pattern Signal Reports - DonanımHaber

Dec 19, 2025

Dec 18, 2025

Protara Therapeutics raises $86.3 million in offering - MSN

Dec 18, 2025

Dec 15, 2025

Protara Therapeutics Raises $86.3 Million in Offering - TipRanks

Dec 15, 2025

Protara Therapeutics, Inc. (NASDAQ: TARA) details $86.3M equity raise from stock sale - Stock Titan

Dec 15, 2025

Dec 14, 2025

What analysts say about Protara Therapeutics Inc stockSwing Trading Ideas & Get Alerts Before Market Turns Ugly - earlytimes.in

Dec 14, 2025

Dec 13, 2025

Acorn Capital Advisors LLC Acquires 472,315 Shares of Protara Therapeutics, Inc. $TARA - MarketBeat

Dec 13, 2025

Dec 10, 2025